2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow CP protocol: new trials by email Literature Review of CP protocol trials Research Report on CP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide, Docetaxel, cyclophosphamide - Breast Cancer | Phase 3 | Terminated | Shanghai Jiao Tong University School of Medicine | 102 | 2009-07-01 | 2016-11-22 |
| Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer PF-3512676 + Paclitaxel + Carboplatin, Paclitaxel + Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Pfizer | 828 | 2005-11-01 | 2015-03-30 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1)
Pfizer (1) · Shanghai Jiao Tong University School of Medicine (1)
China (2) · Australia (1) · Belgium (1) · Canada (1) · Cyprus (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Mexico (1)
Kunwei Shen (1)